July 23, 2026
The IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Study is a new nationwide research initiative designed to improve access to genetic education, counseling, and testing for individuals and families affected by hereditary cancer.The study is jointly led by investigators at Weill Cornell Medicine and The University of Texas MD Anderson Cancer Center. The principal investigators are Dr. Ravi Sharaf and Dr. Melissa Frey of Weill Cornell Medicine and Dr. Jose Alejandro Rauh... Read More
November 19, 2025
We are proud to share that the Weill Cornell Medicine Genetics and Personalized Cancer Prevention (GPCP) Program and our Director, Dr. Melissa Frey, were recently featured in the October Sports Illustrated Swimsuit article, This Breast Cancer Survivor Is Advocating for Equitable Care and Advanced Screenings.The piece spotlights one of our inspiring GPCP... Read More
October 2, 2025
Although multiple factors might affect the utility and eligibility of PARP inhibition in patients with newly diagnosed advanced ovarian cancer, the most important ones may relate to gene alterations found during genetic blood testing, according to Melissa K. Frey, MD.Frey, an associate professor of obstetrics and gynecology in the Division of Gynecologic Oncology and director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine, discussed how the timing of... Read More
May 7, 2025
Congratulations to our 2025 SuperDoctors!Every year MSP Communications compiles a list of SuperDoctors, physicians that have been practicing for over 10 years, and SuperDoctors Rising Stars, physicians that have been practicing less than 10 years. Physicians on the list have been nominated by their peers and are recognized as the best in their field. In the New York Metro area, only about 5% make the cut for... Read More
December 19, 2024
When clinical research professionals think about clinical trials, two types often come to mind: those for critically ill patients, where experimental treatments offer a final chance at survival, and those involving healthy volunteers who participate out of altruism, curiosity, or financial incentives. However, a significant and equally important segment of clinical trials lies in the middle: studies targeting individuals managing chronic conditions or living with the risk of future disease.... Read More
October 28, 2024
BRCA1 mutations dramatically increase the lifetime risk of breast, ovarian, pancreatic, and other cancers, yet most BRCA1-positive patients are not identified until after they have been diagnosed with cancer. At prenatal visits, women often undergo obstetrical prenatal carrier screening that can identify hundreds of genetic mutations which can be passed on to offspring and results in an inherited condition — however, BRCA1 and other autosomal dominant mutations are not included on these... Read More
October 18, 2024
According to the National Cancer Institute, there are many ways to reduce your lifetime cancer risk. You can make mindful food choices, refrain from alcohol, maintain a healthy weight, avoid smoking and stay away from known carcinogens. However, no matter how healthy your lifestyle choices may be, there is no way to change your... Read More
August 30, 2024
Here is a video of Breast Cancer Precision Care: A Family Affair | Weill Cornell Medicine
